| IMMU-10. DEVELOPING NOVEL CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR PAEDIATRIC HIGH GRADE GLIOMA AJ Davenport, L Lertsumitkul, RS Cross, MR Jenkins Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| CAR T-Cell Therapy for Glioblastoma MR Jenkins, KJ Drummond New England Journal of Medicine 390 (14), 1329-1332, 2024 | | 2024 |
| The landscape of genomic structural variation in Indigenous Australians ALM Reis, M Rapadas, JM Hammond, H Gamaarachchi, I Stevanovski, ... Nature 624 (7992), 602-610, 2023 | 7 | 2023 |
| Indigenous Australian genomes show deep structure and rich novel variation M Silcocks, A Farlow, A Hermes, G Tsambos, HR Patel, S Huebner, ... Nature 624 (7992), 593-601, 2023 | 5 | 2023 |
| PHOSPHOPROTEOMIC ANALYSIS OF SECOND GENERATION CHIMERIC ANTIGEN RECEPTOR SIGNALLING FOR THE TREATMENT OF GLIOBLASTOMA R Cross, J Sandow, D Pires, J Yousef, M Iliopoulos, A Webb, M Jenkins HUMAN GENE THERAPY 34 (21-22), A38-A38, 2023 | | 2023 |
| DEVELOPING NOVEL TARGETING CARS FOR GLIOBLASTOMA R Abbott, M Iliopoulos, K Watson, V Arcucci, H Hughes-Parry, P Smith, ... HUMAN GENE THERAPY 34 (21-22), A6-A6, 2023 | | 2023 |
| DESIGNER CAR TRANSMEMBRANE DOMAINS PROVIDE PREDICTABLY TUNABLE T CELL FUNCTIONAL POTENCY M Call, A Elazar, N Chandler, A Davey, J Weinstein, R Trenker, J Nguyen, ... HUMAN GENE THERAPY 34 (21-22), A29-A29, 2023 | | 2023 |
| From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress B Dewdney, MR Jenkins, SA Best, S Freytag, K Prasad, J Holst, ... Signal Transduction and Targeted Therapy 8 (1), 400, 2023 | 7 | 2023 |
| Endogenous H3. 3K27M derived peptide restricted to HLA-A∗ 02: 01 is insufficient for immune-targeting in diffuse midline glioma SS Wang, K Pandey, KA Watson, RC Abbott, NA Mifsud, FM Gracey, ... Molecular Therapy-Oncolytics 30, 167-180, 2023 | 3 | 2023 |
| A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma K Pandey, SS Wang, NA Mifsud, P Faridi, AJ Davenport, AI Webb, ... Frontiers in Oncology 13, 1192448, 2023 | 1 | 2023 |
| Flow Cytometry Identification of Cell Compartments in the Murine Brain JJD Moffet, Z Moore, SJ Oliver, T Towers, MR Jenkins, S Freytag, ... Inflammation and Cancer: Methods and Protocols, 185-198, 2023 | 1 | 2023 |
| Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy K Prasad, RS Cross, MR Jenkins Molecular Oncology 17 (6), 946-949, 2023 | 2 | 2023 |
| HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma SS Wang, AJ Davenport, M Iliopoulos, HE Hughes-Parry, KA Watson, ... Neuro-Oncology Advances 5 (1), vdad024, 2023 | 6 | 2023 |
| Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma RC Abbott, M Iliopoulos, KA Watson, V Arcucci, M Go, HE Hughes‐Parry, ... Clinical & Translational Immunology 12 (3), e1440, 2023 | 5 | 2023 |
| The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells K Richardson, SP Keam, JJ Zhu, D Meyran, C D’Souza, S Macdonald, ... Haematologica 108 (1), 83, 2023 | 3 | 2023 |
| Investigating disparity in access to Australian clinical genetic health services for Aboriginal and Torres Strait Islander people J Luke, P Dalach, L Tuer, R Savarirayan, A Ferdinand, J McGaughran, ... Nature Communications 13 (1), 4966, 2022 | 6 | 2022 |
| BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells D Moujalled, AG Southon, E Saleh, K Brinkmann, F Ke, M Iliopoulos, ... Cell Death & Differentiation 29 (7), 1335-1348, 2022 | 19 | 2022 |
| Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells K Richardson, SP Keam, JJ Zhu, D Meyran, C D'Souza, S Macdonald, ... Haematologica, 2022 | | 2022 |
| De novo-designed transmembrane domains tune engineered receptor functions A Elazar, NJ Chandler, AS Davey, JY Weinstein, JV Nguyen, R Trenker, ... Elife 11, e75660, 2022 | 31 | 2022 |
| To go or not to go? Biological logic gating engineered T cells RC Abbott, HE Hughes-Parry, MR Jenkins Journal for immunotherapy of cancer 10 (4), 2022 | 27 | 2022 |
Joseph A TrapaniPeter MacCallum Cancer Centre, Melbourne Australia在 petermac.org 的电子邮件经过验证
